Adagene Inc
ADAG2.630USD
+0.090+3.54%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
154.94MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Adagene Inc Unternehmen
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
Adagene Inc Informationen
BörsenkürzelADAG
Name des UnternehmensAdagene Inc
IPO-datumFeb 09, 2021
CEOLuo (Peter)
Anzahl der mitarbeiter138
WertpapierartDepository Receipt
GeschäftsjahresendeFeb 09
Addresse4F, Building C14, No. 218, Xinghu Street
StadtSUZHOU
BörseNASDAQ OMX - NASDAQ BASIC
LandChina
Postleitzahl- -
Telefon8651287773632
Websitehttps://www.adagene.com/
BörsenkürzelADAG
IPO-datumFeb 09, 2021
CEOLuo (Peter)
Führungskräfte von Adagene Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.31M
-46664.00%
Dr. Fangyong (Felix) Du, Ph.D.
Dr. Fangyong (Felix) Du, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Xu Jc, M.D., Ph.D.
Dr. Xu Jc, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Zhao Qinghai, Ph.D.
Mr. Zhao Qinghai, Ph.D.
Chief Manufacturing Officer
Chief Manufacturing Officer
--
--
Mr. Tam (Raymond) Man Kin
Mr. Tam (Raymond) Man Kin
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Ms. Gu (Vicky) Chunfang
Ms. Gu (Vicky) Chunfang
Senior Director of Finance
Senior Director of Finance
--
--
Ms. Zhou Ling
Ms. Zhou Ling
Senior Director of Human Resources
Senior Director of Human Resources
--
--
Ms. Li Yan
Ms. Li Yan
Senior Vice President of Bioinformatics and Information Technology
Senior Vice President of Bioinformatics and Information Technology
--
--
Ms. She (Kristine) Xiaohong
Ms. She (Kristine) Xiaohong
Senior Vice President, Head of Clinical Operations
Senior Vice President, Head of Clinical Operations
--
--
Dr. Liu Guizhong, Ph.D.
Dr. Liu Guizhong, Ph.D.
Head of Biology and Pharmacology
Head of Biology and Pharmacology
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.31M
-46664.00%
Dr. Fangyong (Felix) Du, Ph.D.
Dr. Fangyong (Felix) Du, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Xu Jc, M.D., Ph.D.
Dr. Xu Jc, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Zhao Qinghai, Ph.D.
Mr. Zhao Qinghai, Ph.D.
Chief Manufacturing Officer
Chief Manufacturing Officer
--
--
Mr. Tam (Raymond) Man Kin
Mr. Tam (Raymond) Man Kin
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Ms. Gu (Vicky) Chunfang
Ms. Gu (Vicky) Chunfang
Senior Director of Finance
Senior Director of Finance
--
--
Umsatzaufteilung
FY2024
FY2023
FY2022
FY2021
FY2020
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach RegionUSD
Name
Umsatz
Anteil
China (Mainland)
103.20K
0.00%
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sat, Feb 7
Aktualisiert: Sat, Feb 7
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Smith (Vincent C)
10.81%
General Atlantic LLC
8.03%
Olive Tree Capital
7.57%
WuXi AppTec Co, Ltd.
7.00%
Panacea Venture
4.77%
Andere
61.82%
Aktionäre
Aktionäre
Anteil
Smith (Vincent C)
10.81%
General Atlantic LLC
8.03%
Olive Tree Capital
7.57%
WuXi AppTec Co, Ltd.
7.00%
Panacea Venture
4.77%
Andere
61.82%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
13.58%
Investment Advisor
13.28%
Venture Capital
12.37%
Private Equity
8.03%
Corporation
1.93%
Hedge Fund
0.35%
Research Firm
0.16%
Investment Advisor/Hedge Fund
0.02%
Andere
50.28%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
34
16.13M
33.64%
--
2025Q3
35
16.13M
34.15%
+1.22M
2025Q2
33
14.91M
35.61%
-1.53M
2025Q1
31
16.44M
41.65%
-3.18M
2024Q4
29
17.99M
26.58%
+3.27M
2024Q3
27
14.73M
28.57%
+3.50M
2024Q2
28
11.22M
29.45%
-1.07M
2024Q1
30
12.30M
23.60%
+1.88M
2023Q4
27
7.12M
26.44%
-1.20M
2023Q3
33
8.32M
27.49%
-14.57K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
General Atlantic LLC
3.78M
8.03%
-43.61K
-1.14%
Sep 30, 2025
Olive Tree Capital
3.57M
7.57%
--
--
Feb 28, 2025
WuXi AppTec Co, Ltd.
3.30M
7%
-685.45K
-17.21%
Sep 30, 2025
Panacea Venture
2.25M
4.77%
+2.25M
--
Sep 30, 2025
HSG Holding Ltd.
1.34M
2.85%
--
--
Sep 30, 2025
Luo (Peter)
1.31M
2.77%
-46.66K
-3.45%
Feb 28, 2025
Impresa Management LLC
1.29M
2.74%
+1.29M
--
Feb 28, 2025
GP Healthcare Capital Co., Ltd.
910.00K
1.93%
+910.00K
--
Feb 28, 2025
Mill Creek Capital Advisors, LLC
199.61K
0.42%
--
--
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
